Method for obtaining sulfur-containing organomercury compounds

FIELD: pharmacology.

SUBSTANCE: method for production of sulfur-containing organomercury compounds of the formula RS-Hg-SR, where R is

,

or

,

or

,

respectively, by reacting an aqueous solution of mercuric diacetate with cysteine, or glutathione, or acetylcysteine, followed by isolation of the product obtained by filtration, washing with water and drying at a room temperature to the constant weight. The reaction is carried out at a molar ratio of mercury and cysteine or glutathione or acetylcysteine of 1:2, and the reaction mixture is kept at a room temperature for 45-90 minutes.

EFFECT: increased yield of the desired product with a significant simplification of its production method.

3 cl, 4 tbl, 3 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chelated mercury complexes with cysteine of formula C6H13O4N2S2HgCl or methionine of formula C10H21O4N2S2HgCl which show anticancer, antiviral, antiparasitic and immunomodulating action. The invention also concerns a method for preparing the complexes specified above which involves conducting a reaction of mercury dichloride and an aqueous solution of cysteine or methionine, keeping the mixture at temperature 35-40°C for 60-90 min, cooling the reaction mixture to 18-20°C and setting at this temperature for one day. The invention also refers to a drug preparation that is an apoptosis modulator of showing anticancer, antiviral, immunomodulating and antiparasitic action which contains the chelated mercury complex with cysteine or methionine 0.38-0.52 wt % and distilled water.

EFFECT: invention provides preparing the new chelated mercury complexes showing anticancer, antiviral, antiparasitic and immunomodulating action, and also the simplified method for preparing them at lower temperatures.

6 cl, 8 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method of producing concentrates of nanodispersions of zerovalent metals such as silver, gold, copper, palladium, platinum and mercury, which have antiseptic properties. Said method involves mixing a solution of a soluble metal salt in a solvent with ammonia to obtain a complex which is then mixed with alkalnolamine to form a solution. The obtained solution is mixed with a solution of a polymer stabiliser to obtain a stabilised metal cation which is then reduced by adding to the solution an organic or inorganic reducing agent to form a stable dispersion of metal nanoparticles. The disclosed method is realised at a defined ratio of components for 10-60 minutes in an air atmosphere at temperature of up to 100°C.

EFFECT: invention is aimed at obtaining metal dispersions with high sedimentation and chemical resistance and high antiseptic power, which are compatible with a physiological NaCl solution; the method also cuts duration of synthesis and considerably simplifies the process, increases efficiency and complete conversion of cationic metal into a zerovalent metal.

38 cl, 3 tbl, 104 ex

FIELD: medicine.

SUBSTANCE: The invention relates to pharmacology, in particular, to medication for preventing or treating herpes labialis or herpes genitalis. The homeopathic medication or biologically active additive with anti-viral effect or preventing or treating herpes labialis or herpes genitalis contains: Nisylen, Cepa, Euphrasia, Belladonna and Mericulis Solubilis, furthermore, the components are present with a certain dilution and amount. The combination of the said components is used for production of homeopathic medication or biologically active additive with anti-viral effect or preventing or treating herpes labialis or herpes genitalis.

EFFECT: production of medication which effectively treats herpes labialis or herpes genitalis.

14 cl, 1 ex

FIELD: medicine.

SUBSTANCE: said medicine contains Mercurius solubilis C 6, Apis C 3, Belladonna C 3, Pulsatilla C 3, Calcarea carbonica C 6. All medicinal components are taken in the same ratio. The medicine represents sugar granules. Means allows improving clinical effectiveness in treatment for conjunctivitis, quickly managing subjective symptoms (within several hours) and reducing time of treatment due to the integrated effect on all links of the disease process.

EFFECT: medicine is available, reasonably priced, has no contraindications, does not cause an allergic response, can be applied both as a single-drug therapy, and in combination with other medical preparations.

2 cl, 2 ex

FIELD: medicine; veterinary.

SUBSTANCE: for prevention cows in pre-labour period are introduced mercury nitrate "Mercurius solubilis Hahnemmanni" in dose 0.2 g per 100 kg of weight, for treatment dose is doubled.

EFFECT: increase of animal resistance to mastitis disease, considerable reduction of treatment terms.

FIELD: pharmaceutics.

SUBSTANCE: the suggested preparation for treating chronic urological diseases contains perforated St. John's wort grass, common horsetail grass, dog rose fruits, meadow clover grass, flax, elecampane roots at certain ratio of components. The method for preparing the preparation for treating chronic urological diseases deals with washing the raw material, reducing and mixing the components mentioned, removing surface cuticular compounds due to treating the mixture with liquefied carbon dioxide mixture followed by drying and packaging, moreover, the raw material: perforated St. John's wort grass, meadow clover grass, flax seeds, dog rose fruits, elecampane roots, common horsetail grass should be treated under certain conditions. The preparation obtained due to the technique mentioned above is of higher activity for treating chronic urological diseases.

EFFECT: higher efficiency of therapy.

2 cl, 3 ex, 3 tbl

The invention relates to medicine, namely to the treatment of HIV-infected patients
The invention relates to medicine and relates to a means and method for the treatment of skin diseases
The invention relates to medicine and relates to a means and method for the treatment of infectious-inflammatory diseases

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a combination of leucine source and ω-3 polyunsaturated fatty acid source applicable in therapeutic or preventive treatment of hypercalcemia.

EFFECT: invention provides extending the range of products applicable in the therapeutic or preventive treatment of hypercalcemia.

19 cl, 8 dwg, 2 tbl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to medicine and deals with stable composition for provision of subject with therapeutically or prophylactically effective amount of alpha-1 protease inhibitor (API), containing alpha-1 protease inhibitor (API) and at least one amino acid, selected from alanine, threonine, serine or hydroxyproline, where said composition includes one or more auxiliary substances, where at least one amino acid is present in composition in the total amount of amino acid from approximately 0.01 M to approximately 3 M. Group of inventions also deals with set for treatment or prevention of API-associated disease or condition, which includes said composition; application of at least one amino acid, selected from alanine, threonine, serine or hydroxyproline, for stabilisation of composition, containing alpha-1 protease inhibitor (API).

EFFECT: group of inventions provides stability of API composition.

15 cl, 27 dwg, 5 tbl, 8 ex

FIELD: veterinary medicine.

SUBSTANCE: composition comprises succinic acid, trace elements in the form of sulphates of iron, copper, cobalt, zinc and additionally comprises methionine and beet-root molasses at the following content of components in 1000 ml of an aqueous solution: succinic acid - 5.0 g, beet-root molasses - 150.0 ml, methionine - 2.0 g, ferrous sulphate - 10.0 g, copper sulphate - 0.1 g, cobalt sulphate - 0.5 g, zinc sulphate - 0.5 g.

EFFECT: use of the claimed composition has a positive effect on the immune-metabolic status and growth activity of piglets.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, namely to dermatology, and can be used for preventing and/or treating skin itching. It involves using L-serine as a therapeutic agent, a pharmaceutical composition containing L-serine, as well as a dermato-cosmetic composition containing L-serine as a single active agent, Avene Thermal Spring Water, glycerine and a cosmetically acceptable carrier. The L-serine concentration in the composition makes from 0.01 wt % to 10 wt % in relation to the total weight of the composition. More preferentially, the concentration makes 0.5 wt % to 3 wt % in relation to the total weight of the composition.

EFFECT: group of inventions provides the effectiveness of application.

8 cl, 2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents an agent for preventing or reducing pigmentation, containing a compound presented by the following formula (1) its stereoisomer and/or its pharmacologically acceptable salt, wherein: R1 represents a hydrogen atom or an alkyl group with a linear or branched chain having 1-4 carbon atoms; R2 represents a hydrogen atom or an unsubstituted aliphatic hydrocarbon group having 1-4 carbon atoms; R3 represents an unsubstituted aromatic group having 5-15 carbon atoms, substituted by an alkyl group having 1-6 carbon atoms, by an alkoxy group containing an alkyl chain having 1-6 carbon atoms, or by a phenyl group; R3 also represents an aromatic group having 5-15 carbon atoms; n is equal to 1 or 2, and m represents an integer falling within 0 to 3.

EFFECT: preparing the agent for preventing or reducing pigmentation.

10 cl, 10 ex, 6 tbl

FIELD: biotechnology.

SUBSTANCE: invention relates to a biodegradable synthetic polymer, namely to the polymer of the general formula (I) , where NA has the structure: , AN has the structure: , where n is an integer >2; Z is either absent or is an amino acid residue -NH-(CH2)i-CO-, where i - is an integer from 1 to 5; D represents a linear or branched alkyl C1-C5 or benzyl; B represents a residue of aliphatic diamine -NH-(CH2)k-NH-, where k is an integer from 2 to 6; X and Y can simultaneously have the following meanings: X=H-B, Y=H, or X=Nα-(D-OCO)-L-arginyl-Z-B, Y=Nα-(D-OCO)-L-arginyl-Z, or X=R1-AN-B, Y=NA-R1, where R1 is carboxamide-alkyl of the type H2NCO-CH2- or H2NCO-CH2CH2-. Such a polymer is capable of delivering the natural L-arginine into the tissues of human, animals, through biological membranes and can be used alone or in a combination with other active compounds.

EFFECT: invention enables to obtain the polymer soluble in water, which has no cytotoxicity and enhances the level of nitrogen oxide in the tissues of humans and animals.

2 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention represents a balanced infusion solution containing sodium, potassium and magnesium chlorides, a solvent and sodium L-arginine succinate of formula: Na+[NH=C(NH2)NH(CH2)3CH(NH2)COOH]+[OOC(CH2)2COO]2-. The ingredients in the solution are found in certain proportions, wt %.

EFFECT: invention provides enhanced detoxification activity, low toxicity and wide range of clinical applications.

11 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to a method of treating a mammal with endometriosis. The claimed method includes the pulse or interrupted peroral introduction of an N-acetyl-L-cysteine-containing pharmaceutical composition for 3-5 successive days with the following 2-4-day break or for 1-3 successive days with the following 1-2-day break, for at least a two-month time period. N-acetyl-L-cysteine in the said method is introduced in a dose, constituting from 20 to 90 mg/kg/day.

EFFECT: claimed method provides the more significant effect with respect to endometriosis symptoms in comparison with the traditional daily introduction of N-acetyl-L-cycteine.

11 cl, 7 dwg, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to traumatology and orthopaedics, and can be used for treating proximal humeral injuries. That is ensured by three-staged complex therapeutic actions. At the first stage, setting of fracture and reduction of humeral head dislocation is followed by immobilising an extremity by continuous twenty-four hour brace fixation of the proximal humerus with Desault's bandage for the period of 4 weeks. From the first therapeutic day, the patient does daily 30-minute therapeutic exercises, including isometric, static and ideomotor exercises to strengthen his/her arm muscles and to improve the circulation. That is combined with a complex reparative drug therapy. At the first stage, the anti-inflammatory preparation Arthrofoon is administered orally, while vasodilators improving nicotinic acid, trental or complamin microcirculation are injected intramuscularly daily for 10 days. The enzymatic preparations Wobenzyme or Flogenzyme are also administered in a dose of 3 tablets three times a day for 3-4 weeks. The second stage starting two weeks after the beginning of the treatment involves electric stimulation (ES) by exposing the collar and shoulder muscles from the involved side for 30 minutes to electric signals generated by an electric myostimulation device. The ES procedure requires the patient to perform 15-minute active motions by a healthy arm, and for the following 15 minutes the patient is expected to tense and relax alternatively the muscles from involved side. The therapeutic exercises are also done. The drug treatment regimen of the second stage implies administering the preparations Calcemin or Calcemin Advance for six months. That is combined with 10 daily intramuscular injections of the preparation Milgamma 2 ml. At the third stage 4 weeks after the beginning of the treatment, control X-ray imaging is followed by removing the brace. Accompanied by the reparative drug therapy continued, the complex therapeutic actions provide local injection therapy in number of 8-10 daily procedures. The biologically active reflex areas nearby the involved joint are pre-exposed to focused red laser light, and the mixed preparations Alflutop, or other chondroprotector, vitamin B12, Contrykal or Lidase, Lidocaine are injected in the same areas. Two weeks after the brace has been taken off, the patient keeps doing the therapeutic exercises twice a week continuously. The drug therapy and local injections are repeated six months later. The brace is further required for the following year if the patient is supposed to bear occupational or sports physical loads.

EFFECT: method provides faster recovery of the extremity functionality, prevents posttraumatic degenerative process in the humeral joint, recurred dislocation formation, humeral instability and contractures by optimising the humeral para-articular tissue health, improving the quality of bone tissues, first of all, of the subchondral plate and humeral head.

2 cl, 1 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: composition has an action of the central nervous system; it is presented in the form of a solution, contains glycine, glycerol, a preserving agent and water. The invention also concerns a therapeutic agent and a biologically active addition based on the above composition.

EFFECT: group of inventions provides high bioavailability as the composition is presented in the liquid and ease of dosing.

12 cl, 2 tbl, 3 ex

FIELD: medicine, cardiology.

SUBSTANCE: the suggested method should be performed at the background of medicinal therapy with preparations out of statins group, tevetene, polyoxidonium and conducting seances of plasmapheresis by removing 800 ml plasma twice weekly with N 5 due to additional intramuscular injection of immunophan 0.005%-1.0 with N 10 and fluimucyl 300 mg intravenously daily with N 5-10, total course of therapy lasts for 2 mo. The method provides modulation of leukocytic functional activity, moreover, due to altered cytokine profile and, thus, through disintegration of protein-lipid complexes participating in the development of atherosclerotic platelets.

EFFECT: higher efficiency of therapy.

3 ex

Up!